Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CADI-05 in Advanced Melanoma
NCT00675727Phase 2Terminated
- Sponsor
- Cadila Pharmaceuticals
- Start
- Dec 2006
- Primary completion
- Dec 2010
- Modality
- Prophylactic Vaccines, Microbiome Therapeutics, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MYCIDAC-C in melanoma, sponsored by Cadila Pharmaceuticals. Started Dec 2006; status: terminated.
02
Drugs
MYCIDAC-C
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00675727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00675727.